Hyperprolactinemia

Definition and Normal Values

• Prevalence: <1% of the general population, but up to 14% of women with abnormal menses
• PRL >200 ng/mL strongly suggests a prolactinoma (macroadenoma)

Physiology of Prolactin

• Secreted by lactotropes of the anterior pituitary
• Primarily under tonic inhibitory control by hypothalamic dopamine (DA) - dopamine keeps PRL suppressed under normal conditions
• Stimulatory factors: TRH, VIP, estrogen, serotonin, opioids
• Main physiologic roles: mammary gland development and lactation; suppresses GnRH pulsatility

Etiology / Causes

I. Physiologic

II. Pharmacologic (Drug-Induced) - Very Common

• Antipsychotics (risperidone, haloperidol, phenothiazines) - risperidone can push PRL >200 ng/mL
• Antidepressants (TCAs, SSRIs less so)
• Antiemetics (metoclopramide, domperidone, prochlorperazine)
• Antihypertensives - methyldopa (inhibits DA synthesis), verapamil (blocks DA release)
• Opioids / H2 blockers (cimetidine)
• Estrogens (directly stimulate lactotropes)
• Drug-induced PRL is typically <100 ng/mL

III. Pathological - Pituitary / Hypothalamic

IV. Systemic Disease

• Primary hypothyroidism - elevated TRH compensatorily stimulates both TSH and PRL (always check TSH)
• Chronic renal failure - reduced peripheral PRL clearance
• Cirrhosis - impaired PRL metabolism
• Polycystic ovarian syndrome (PCOS) - up to 30% have mildly elevated PRL

V. Macroprolactinemia (Artifact)

Pathophysiology of Symptoms

• Women: low estrogen → menstrual irregularity → oligomenorrhea → amenorrhea; infertility; osteopenia (direct PRL effect + indirect estrogen deficiency)
• Men: low testosterone → decreased libido, impotence, oligospermia, reduced muscle mass, osteopenia; late presentation since male hypogonadism symptoms are subtle
• Both sexes: galactorrhea (PRL drives milk production when breast tissue is primed by estrogen)

Clinical Features

Women (Premenopausal)

• Amenorrhea or oligomenorrhea (most common presenting symptom)
• Galactorrhea - present in up to 80%; may be bilateral/spontaneous or unilateral/manual
• Infertility (anovulation)
• Decreased libido, vaginal dryness
• Mild hirsutism and weight gain
• Osteopenia/osteoporosis (with sustained hypoestrogenemia)
• Primary amenorrhea if onset before menarche

Note: Postmenopausal women do not develop galactorrhea despite elevated PRL because estrogen priming is absent.

Men

• Decreased libido, impotence (usually the presenting complaint)
• Oligospermia, infertility
• Osteopenia, reduced muscle mass, decreased beard growth
• Galactorrhea - rare (requires elevated estrogen, e.g., in cirrhosis)
• Visual field defects (bitemporal hemianopsia from optic chiasm compression by large tumor) - men often present late with macroadenomas
• Headaches

Diagnosis

Step 1: Serum PRL

• Measure under resting conditions (minimal stress, no breast stimulation, morning sample)
• Borderline elevation: repeat on at least 2 separate occasions
• PRL >200 ng/mL: very likely prolactinoma (macroadenoma)
• PRL 100-200 ng/mL: adenoma possible; MRI mandatory
• PRL <100 ng/mL: microadenoma, drug-induced, stalk effect, or systemic cause

Step 2: Exclude Secondary Causes

• TSH - rule out hypothyroidism
• Serum creatinine/BUN - rule out renal failure
• Pregnancy test (urine/serum hCG) in all women of reproductive age
• Drug history (careful medication review)
• Consider macroprolactin if PRL is mildly elevated with no symptoms (PEG precipitation assay)

Step 3: MRI of the Pituitary

• Indicated in all patients with:
  • PRL >100 ng/mL
  • Symptomatic hyperprolactinemia (galactorrhea, amenorrhea, visual symptoms)
  • No obvious drug/systemic cause
• Classifies tumor as microadenoma (<1 cm) or macroadenoma (≥1 cm)
• For macroadenomas: also perform formal visual field testing (Goldman or Humphrey perimetry)

Treatment

Treat the Underlying Cause First

• Drug-induced: withdraw offending drug if possible; for psychiatric patients, supervised dose reduction, drug switch (e.g., quetiapine has lower PRL-elevating potential), or cautious DA agonist co-administration (note: DA agonists may worsen psychosis)
• Hypothyroidism: thyroid hormone replacement normalizes PRL
• Renal failure: PRL often normalizes after successful renal transplantation
• Stalk compression by non-functioning tumor: surgical resection can reverse hyperprolactinemia
• Idiopathic hyperprolactinemia: spontaneous resolution occurs in up to 30% of cases; only treat if symptomatic

Dopamine Agonists - First-Line for Prolactinomas

Cabergoline (preferred)

• Dose: 0.5-1.0 mg orally twice weekly, titrated to lowest effective dose
• Achieves normoprolactinemia in ~80% of microadenomas and ~70% of macroadenomas
• Reduces tumor size in 80-90% of macroprolactinomas
• Long half-life (>14 days after single dose); better tolerability than bromocriptine
• Galactorrhea resolves in 90% of patients
• Visual field defects can begin improving within days
• Caution: doses >2 mg/week long-term - concern for cardiac valve fibrosis (particularly tricuspid); echocardiogram recommended yearly for patients on >5 mg/week or with known valvular disease

Bromocriptine

• Dose: start 0.625-1.25 mg at bedtime with a snack, gradually increased to 2.5-15 mg/day
• Preferred when pregnancy is desired (more safety data in pregnancy; short-acting so can be stopped quickly once pregnant)
• More GI side effects (nausea, vomiting, dizziness) than cabergoline
• Can be administered vaginally in women to improve tolerability

Monitoring Response

• PRL measured at regular intervals after dose adjustments
• For macroadenomas: repeat MRI within 16 weeks of starting therapy; then annually
• Target PRL: <10 ng/mL (Goldman-Cecil recommendation)
• ~20% of patients (especially males) are resistant to dopaminergic treatment due to decreased D2 receptor numbers

Stopping Therapy

• Microadenomas: after 2+ years of normoprolactinemia and significant tumor shrinkage, may cautiously withdraw DA agonist with close monitoring; ~5% achieve permanent remission
• PRL and MRI repeated at 3 months, 6 months, then annually after stopping
• Macroadenomas: higher recurrence risk; generally require longer treatment

Surgery (Transsphenoidal Adenomectomy)

• Indicated when:
  • DA agonist intolerance or resistance
  • Tumor growth despite medical therapy
  • Apoplexy with acute visual loss
  • Patient preference (desire for drug-free state)
• Cure rates: ~70-80% for microadenomas, ~30% for macroadenomas
• Risk of CSF leak, hypopituitarism, diabetes insipidus

Radiotherapy

• Reserved for aggressive or malignant prolactinomas unresponsive to drugs and surgery
• Stereotactic radiosurgery (Gamma Knife) for well-defined residual tumors
• Risk of delayed hypopituitarism

Prolactinoma in Pregnancy

• Women with microprolactinomas: very low risk of clinically significant tumor growth during pregnancy (~2-5%); bromocriptine/cabergoline can be stopped once pregnancy is confirmed
• Macroadenomas: ~25% grow significantly during pregnancy; continue dopamine agonist or consider surgery if vision threatened; monitor visual fields each trimester
• Prolactin levels rise physiologically during pregnancy, so PRL measurements are not useful for monitoring tumor growth - rely on symptoms and visual fields

Treatment Algorithm

MRI Response to Cabergoline

Key Differentiating Points

Recent Evidence (PubMed 2024-2026)

• A network meta-analysis (2025) [PMID: 39411853] comparing aripiprazole, bromocriptine, and cabergoline found cabergoline had superior efficacy and favorable safety for hyperprolactinemia treatment.
• A meta-analysis (2024) [PMID: 38945085] in women with PCOS and hyperprolactinemia showed metformin + cabergoline was more effective than metformin alone for reducing prolactin and improving ovulation.
• A systematic review (2024) [PMID: 39627209] in systemic lupus erythematosus found elevated prolactin correlates with disease activity and dopaminergic agonists modestly reduce both prolactin and disease activity.